NCT05516121View on ClinicalTrials.gov

VLT-015 in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

October 30, 2022

Conditions
Schizophrenia
Interventions
DRUG

VLT-015

100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days

Trial Locations (2)

115522

"Federal State Budgetary Scientific Institution Mental Health Research Centre", Moscow

355038

GBUZ SK Stavropol Regional Clinical Specialized Psychiatric Hospital No. 1, Stavropol

Sponsors

Lead Sponsor

CF Pharma, LLC
All Listed Sponsors
lead

CF Pharma, LLC

INDUSTRY